Grace Therapeutics, Inc. Interest Receivable
Grace Therapeutics, Inc. (GRCE) had Interest Receivable of $143.00 thousand as of 2023-03-31, per its 10-K filed 2023-06-23.
Discontinued › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2023-06-23
- 2023-03-31: Interest Receivable $143.00K.
- 2022-03-31: Interest Receivable $71.00K.
| Period end | Interest Receivable |
|---|---|
| 2023-03-31 | $143.00K 10-K · filed 2023-06-23 |
| 2022-03-31 | $71.00K 10-K · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |